Skip to content
    PTCT
    Earnings call· Jun 2026(Q2 FY26)

    PTC THERAPEUTICS Q2 FY26 earnings call PTCT

    Jul 30, 2026 Source

    Executive summary

    PTC Therapeutics Q2 FY26 — Record Revenue and Raised Guidance Driven by Strong Sephience Launch

    PTC Therapeutics delivered a strong second quarter, driven by the continued robust global launch of Sephience, which saw significant revenue growth and broad market penetration. The company raised its full-year revenue guidance, reflecting confidence in Sephience's trajectory and the unexpected durability of the DMD franchise. Progress in the pipeline, including positive votoplam data and advancement of other clinical programs, further supports the long-term growth outlook, while a strong cash balance provides strategic flexibility.

    Highlights

    5

    • Achieved record total revenue of $361 million, including $239 million in product revenue, representing over 100% YoY growth.

    • Raised full-year 2026 product revenue guidance to $850 million-$950 million and total revenue guidance to $1.18 billion-$1.28 billion.

    • Sephience global revenue reached $151 million, growing 21% QoQ, with 1,647 commercial patients globally and 100% penetration in US centers of excellence.

    • Votoplam's PIVOT-HD study showed positive 24-month interim results with a 52% slowing of disease progression in the 10mg Stage 2 cohort.

    • Maintained a strong cash position of $2.23 billion as of June 30, 2026, following a successful convertible note refinancing.

    Concerns

    2

    • DMD franchise (Translarna and Emflaza) continues to face headwinds from generic pressure and challenges in key international markets.

    • Sephience discontinuation rate remains at approximately 20%, though management views this as impressive given early patient profiles.

    Guidance & targets

    8
    CategoryTargetConfidence
    Full-year 2026 product revenue
    $850M-$950M
    high materiality
    High
    Full-year 2026 total revenue
    $1.18B-$1.28B
    high materiality
    High
    Cash flow breakeven
    potentially reach
    medium materiality
    Medium
    Sephience global commercial opportunity
    $2B+
    high materiality
    High
    International revenue contribution for Sephience
    increasingly contribute
    medium materiality
    High
    Germany Sephience pricing and reimbursement
    finalized
    medium materiality
    High
    France Sephience pricing and reimbursement
    conclude sometime next year
    medium materiality
    Medium
    Italy and Spain Sephience pricing and reimbursement
    conclude sometime in early 2027
    medium materiality
    Medium

    Segment performance

    5
    SegmentRevenueYoYQoQMargin
    Sephience
    Strong global launch momentum with increasing contributions internationally, exceeding internal expectations in Japan. Broad uptake across patient segments and age groups worldwide.
    Commercial patients globally: 1,647 (as of June 30, 2026)US Centers of Excellence penetration: 100%
    		$151M—21%—
    DMD franchise
    Continued sales despite challenges from generic pressure for Emflaza and headwinds in some larger countries for Translarna.
    		$67M———
    Translarna
    Includes a government purchase order from Russia, with continued sales in Europe and Latin America.
    		$42M———
    Emflaza
    Continues to see new prescriptions and ongoing brand loyalty despite generic pressure.
    		$25M———
    Evrysdi
    Royalty revenue generated from Roche's global sales of Evrysdi.
    Royalty revenue: $71MRoche global revenue: ~$628M
    		————

    Operational metrics

    8
    Total product and royalty revenue
    $310M
    Q2 FY26
    Total net product revenue
    $239Mup >100% YoY
    Q2 FY26
    Non-GAAP R&D expense
    $89Mdown from $104M in Q2 FY25
    Q2 FY26
    Non-GAAP SG&A expense
    $68Mdown from $76M in Q2 FY25
    Q2 FY26
    Cash, cash equivalents and marketable securities
    $2.23Bup from $1.95B as of Dec 31, 2025
    as of June 30, 2026
    Convertible notes refinancing
    majority of 2026 notes
    Q2 FY26

    Strategic management of 2026 convertible note liability.

    Sephience discontinuation rate
    20%
    Q2 FY26

    Defined as 60 days or 2 months without prescription renewal. Considered low and impressive by management.

    Sephience prescription renewal rate
    >90%
    Q2 FY26

    Industry KPIs

    3
    MetricValueDetails
    Peak long term sales guidance$2B+USD
    Clinical trial efficacy safety data52% slowing%
    Collaboration milestone royalty revenue$71MUSD

    Deals & partnerships

    1
    NovartisCollaboration on votoplam Huntington's disease program

    Novartis initiated enrollment in the global Phase III INVEST-HD study, which is being conducted and funded by Novartis. Novartis and PTC teams are finalizing a plan to engage with FDA in H2 2026 to discuss 24-month results and potential accelerated path.

    Risks & headwinds

    3
    DMD franchise generic pressureongoing

    significant number of generics now for Emflaza

    Mitigation: ongoing brand loyalty attributable in part to our programs and continued high-touch white glove services from our PTC Cares team

    DMD franchise international headwindsongoing

    headwinds in some of the larger countries where we get group purchase orders

    Mitigation: continued sales in Europe and Latin America as well as the government order from Russia

    Translarna selling in Europe without a licenseongoing

    not quantified

    Mitigation: continued sales in Europe and Latin America

    What to watch in Q3 FY26

    5

    Votoplam FDA discussion on accelerated path

    H2 2026
    CurrentPTC and Novartis finalizing plan to engage FDA in H2 2026.
    TargetFDA's receptiveness to accelerated path based on 24-month PIVOT-HD data.

    Why it matters

    Could significantly accelerate market access for a disease-modifying therapy for Huntington's disease.

    the Novartis and PTC teams are finalizing a plan to engage with FDA in the second half of 2026 to discuss the 24-month results and potential accelerated path.

    Q&A highlights

    8

    What is the estimated US patient penetration for Sephience (around 10% of 17,000 population)? What percentage of patients might try the therapy? What are the key goals for upcoming medical conferences?

    The company is excited about early demand but acknowledges a long way to go, with 100% penetration into US centers of excellence. They estimate about 70% of individuals tried Kuvan, suggesting a large untapped population. Conference goals include promoting awareness, demonstrating benefits for classical PKU and BH4 non-responsive patients, and reinforcing data for switches from generic therapies.

    “I think when we look to metrics thus far and we see penetration into 100% of the centers of excellence, that's really an incredible milestone this early, and it basically puts us in the position we want to be with a strong base of patients to now go deeper and deeper into those centers.”

    asked by Kristen Kluska · answered by Matthew Klein

    2 min read7 chapters

    Detailed Narrative

    01

    Sephience Global Launch Momentum

    PTC Therapeutics reported record Sephience global revenue of $151 million, a 21% sequential increase, with 1,647 commercial patients globally as of June 30, 2026. The US market achieved 100% penetration of centers of excellence, with broad uptake across all patient segments and age groups. International momentum is building, with strong early uptake in Japan and accelerated demand in European early access programs, reinforcing confidence in the $2 billion-plus global opportunity.

    02

    Votoplam Huntington's Disease Program

    Positive 24-month interim analysis results from the PIVOT-HD study demonstrated dose-dependent slowing of disease progression on cUHDRS, including an average 52% slowing relative to natural history in the 10mg Stage 2 cohort, with a favorable safety profile. Novartis has initiated enrollment in the global Phase III INVEST-HD study, and discussions with the FDA are planned for H2 2026 to explore a potential accelerated approval path.

    03

    Vatiquinone Friedreich's Ataxia Program

    The company finalized the study protocol for PROVE-FA, an open-label trial with a natural history comparator arm, to support NDA resubmission for vatiquinone. The study, enrolling approximately 120 individuals aged 7-21 with a primary endpoint of mFARS change at month 24, is expected to initiate in Q3 FY26, reflecting key learnings from prior development.

    04

    Advancing Clinical Pipeline Programs

    PTC initiated a Phase I study for PTC612, an oral NLRP3 inhibitor, with early PK/PD data expected by year-end or early next year, focusing on rare pulmonary disorders. A Phase IIa study for PTC844, a next-generation DHODH inhibitor, is planned for Q3 FY26 to assess biomarker effects in rheumatoid arthritis patients and inform future indications.

    05

    MSH3 Splicing Program (PTC303)

    A development candidate, PTC303, was selected for the MSH3 splicing program, targeting triplet repeat expansion diseases like Huntington's and myotonic dystrophy. This fully owned asset is expected to enter the clinic in 2027, offering a complementary approach to HTT lowering and reinforcing PTC's leadership in small molecule splicing therapies.

    06

    Financial Strength and Capital Management

    PTC closed the quarter with a strong cash, cash equivalents, and marketable securities balance of $2.23 billion, up from $1.95 billion at year-end 2025. This was supported by the strategic refinancing of the majority of 2026 convertible notes into new 2031 notes with a 0% coupon and 40% conversion premium, providing flexibility for future growth and supporting the goal of cash flow breakeven in 2026.

    07

    International Market Expansion for Sephience

    Beyond the US, Sephience is gaining significant traction in international markets. Japan's early launch results exceeded expectations with rapid uptake and pricing on par with the US, locked in for 10 years. Early access programs in France, Italy, and Spain are showing accelerated demand, with pricing and reimbursement discussions ongoing, expected to conclude in late 2026 or early 2027 for these markets.

    AI-generated summary of the company’s earnings call. Not investment advice.